Subsequently, numerous studies reported that overexpression of PRAME was significantly correlated with clinicopathological features in malignant tumours, including medulloblastoma [6], hepatocellular carcinoma [7, 8], adenocarcinoma [9], uveal melanoma [10, 11], high-grade serous cancer [12], myxoid liposarcoma [13], diffuse large B-cell lymphoma [14], osteosarcoma [15], bladder cancer [16], breast carcinoma [17, 18], and neuroblastoma [19]. The gene discussed is PRAME; the disease is urinary bladder carcinoma.